Ultragenyx Pharmaceutical
RARE
239 hedge funds and large institutions have $4.79B invested in Ultragenyx Pharmaceutical in 2022 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 90 increasing their positions, 74 reducing their positions, and 31 closing their positions.
26% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 31
22% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 74
2% more funds holding
Funds holding: 234 → 239 (+5)
2.23% less ownership
Funds ownership: 99.25% → 97.03% (-2.2%)
16% less capital invested
Capital invested by funds: $5.69B → $4.79B (-$893M)
54% less call options, than puts
Call options by funds: $7M | Put options by funds: $15.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$34.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25M |
| 3 |
State Street
Boston,
Massachusetts
|
+$18.8M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$16M |
| 5 |
O
OrbiMed
New York
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$141M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$35.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$34.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.93M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.47M |
RARE Hedge Fund Activity: Q1 2022 in Review
239 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q1 2022, worth a combined $4.79B — down 16% from $5.69B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new RARE positions and 31 closed out — a net gain of 8 holders — while 90 added to existing stakes and 74 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $34.3M. The largest seller was Capital International Investors, cutting an estimated $141M.
- 239 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q1 2022, up from 234 in Q4 2021.
- Funds reported $4.79B of Ultragenyx Pharmaceutical stock for Q1 2022, down 16% quarter-over-quarter.
- 39 funds opened new Ultragenyx Pharmaceutical positions in Q1 2022 and 31 closed out, a net change of +8 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q1 2022 was Wellington Management Group, an estimated $34.3M added.
- The largest Ultragenyx Pharmaceutical seller in Q1 2022 was Capital International Investors, an estimated $141M sold.
Based on aggregated 13F filings for Q1 2022.